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Synthetic biology is a nascent technical discipline that seeks to enable the design and construction of novel biological systems
to meet pressing societal needs. However, engineering biology still requires much trial and error because we lack eﬀective
approaches for connecting basic “parts” into higher-order networks that behave as predicted. Developing strategies for improving
the performance and sophistication of our designs is informed by two overarching perspectives: “bottom-up” and “top-down”
considerations. Using this framework, we describe a conceptual model for developing novel biological systems that function and
interact with existing biological components in a predictable fashion. We discuss this model in the context of three topical areas:
biochemical transformations, cellular devices and therapeutics, and approaches that expand the chemistry of life. Ten years after
the construction of synthetic biology’s ﬁrst devices, the drive to look beyond what does exist to what can exist is ushering in an era
of biology by design.
1.Introduction
Our understanding of physical laws and knowledge of
material properties allow us to engineer bridges that do not
collapse and car engines that convert energy into mechanical
motion. Engineering biology, however, is diﬀerent. Even the
simplest bacterium comprises a system whose complexity
is humbling [1, 2]. In recognition of such challenges, the
centralgoalofsyntheticbiologyistotransformbiologyintoa
systemthatcanbeengineeredjustasweengineerbridgesand
mechanicalsystemstoday(reviewedin[3–8]).Thisapproach
promises to provide an improved understanding of the living
world and will enable us, in the coming years, to harness
the diverse repertoire of biology for compelling applications.
These include next-generation biofuels, renewable “green”
chemicals and industrial feedstocks, programmable and
personalizable biological therapies, materials with novel
properties, cheap and deployable diagnostics and therapeu-
tics to promote global health, and technologies enabling
environmental stewardship and remediation. The guiding
question is this: how can we make biology engineerable? The
new paradigm of biology by design can be summarized as
follows:
(i) conceive a desired biological function,
(ii) design an engineered biological system to perform
this function,
(iii) build the system,
(iv) the system performs as predicted.
Achieving this ambitious goal will require an improved
understanding of the mechanisms by which biological parts
function and by which they interact with one another and
their environment.
The ﬁrst wave of synthetic biology has focused on
the development of simple biological modules, involving
anywhere between two and ten well-characterized biological
“parts” (e.g., genes) that are connected to perform deﬁned
functions(reviewedin[7]).Inprinciple,these“parts”should
still operate in a predictable manner when transplanted
intodiﬀerentbiologicalcontexts.Thisconceptualframework2 Journal of Biomedicine and Biotechnology
connects synthetic biology with other engineering disci-
plines. Whether the parts are electrical, chemical, physical,
or biological, engineers depend on the predictable behavior
of connected components to design and construct com-
plex systems. For example, the automotive industry must
develop engines that work within the context of an entire
automobile. Construction of an engine is possible due to
an understanding of how the individual components (e.g.,
pistons, crankshafts, and spark plugs) interact with one
another, how these individual functions can be assembled
to achieve a desired task (e.g., conversion of energy released
by combusting fuel into mechanical motion), and how this
assembled system interacts with the broader context of the
vehicle (e.g., drawing fuel from the fuel lines and powering
the transmission to transmit energy to the wheels). When
synthetic biologists design simple biological systems from
individual components in order to perform novel functions,
these systems often do not behave as expected, particularly
when transported from one biological context to another. In
eﬀect, a synthetic biologist today must endeavor to design
an engine from imperfectly characterized parts and without
knowing how the engine will eventually connect to the rest
of the vehicle.
To overcome the limitations of our incomplete knowl-
edge of biology, synthetic biologists approach the con-
struction of user-deﬁned functions through an iterative
design cycle that incorporates both bottom-up and top-
down design perspectives (Figure 1).
Bottom-upconsiderationsincludethefollowing:What
is the desired function of the synthetic system? What
parts could be used to construct this system (e.g.,
promoters,ribosomebindingsites,etc.)?Dotheparts
exist and do they require additional characteriza-
tion? How should the parts be conﬁgured? What
is the predicted behavior of the synthetic module?
Conceptually, this design perspective focuses on the
characteristics of individual modules (which may be
parts or subnetworks of parts) and their assembly
into novel conﬁgurations in isolation from the
endogenous cellular context into which they will
eventually be placed.
Top-down considerations include the following: How
might the engineered module be decoupled from
or insulated from aspects of the broader biological
context (e.g., metabolic state, cell cycle progression,
and epigenetic modiﬁcations) that may complicate
the function of the engineered network? What inter-
actionsarenecessarytoconnectasyntheticcontroller
to the endogenous system it will control? How can
the synthetic system take advantage of the existing
biological infrastructure? The top-down perspective
focuses on potential interactions—both desirable
and undesirable—between the engineered subsystem
and its biological context, and on development of
strategies for harnessing or compensating for these
inﬂuences.
Top-down and bottom-up perspectives guide our devel-
opment of improved strategies for engineering biology
Top-down perspective
Interactions Orthogonality
Analysis
in context
Biological
design
Construction
and implementation
Conﬁgurations Modules
Bottom-up perspective
Figure 1: General conceptual framework for incorporating top-
down and bottom-up perspectives in the synthetic biology design
process. Due to our incomplete knowledge of biology, the design
of biological systems through synthetic biology is currently an
iterative process that incorporates both top-down and bottom-
up design considerations. First, a design objective is identiﬁed.
Next, a suitable synthetic biological system is designed given the
known properties of well-characterized components (bottom-up).
The synthetic system is then constructed and inserted into a larger
biological context with which the synthetic system may interact
(top-down), and performance of the combined system is assessed.
If the system fails to meet performance requirements, this new
information can be used to reﬁne the design and repeat the cycle.
Our ever-improving understanding of biology should reduce the
numberofiterationsnecessarytoachieveaspeciﬁcdesignobjective.
(Figure 1), even in the face of incomplete information.
Here, we discuss these perspectives in the context of three
rapidly progressing areas which exemplify the opportunities
and challenges encountered at diﬀerent scales of biological
organization: biochemical transformations, cellular devices
and therapeutics, and approaches that expand the chemistry
of life (Figure 2). Each of these topics is leading to new
applications and advancing frontiers in synthetic biology.
2.Applications andNew Frontiers
2.1. Biochemical Transformations. In the nearly four decades
since the molecular biology revolution, it has become
clear that the biological world provides a rich and diverse
repertoire that may help to address some of humanity’s
most signiﬁcant challenges. For example, harnessing biology
for production of small molecules has led to applications
in biofuels, chemical feedstocks, and therapeutics [3, 9].
However, to achieve these advances, substantial investments
of resources, time, and labor are currently necessary. For
example, it has been estimated that engineering microbes forJournal of Biomedicine and Biotechnology 3
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Figure 2: Application of the general framework to speciﬁc design objectives. At each scale of biological organization, designing synthetic
biological systems invokes unique instances of the top-down and bottom-up considerations described in Figure 1.
expressionoftheantimalarialdrugartemisininrequired150-
person years of work [10].
Biochemical transformations comprise a family of appli-
cations for which synthetic biology may complement and
expand eﬀorts in metabolic and genetic engineering, by
providing a robust technological framework for addressing
common challenges. These challenges include targeting
substrate ﬂux towards a speciﬁc product, avoiding the
loss of intermediates to competing pathways, reducing
the accumulation of toxic intermediates, and preventing
saturation of pathway enzymes [11, 12]. Synthetic biology
tools are used to remove rate-limiting steps and increase
titers of target biochemicals through an iterative design cycle
of analysis, design, and implementation (Figure 1). Each
cycle invokes both bottom-up and top-down considerations
(Figure 2). Bottom-up considerations may include gene
selection,promoterselection,anduseofregulatoryelements.
Top-down considerations may include selection of the host
organism, potential interactions of the synthetic metabolic
network with existing cellular components, and competition
with native pathways that impact substrate or intermediate
availability. Host selection must often include making a
choice between transferring heterologous pathways to a
well-characterized organism or improving the production
capacity (or other properties) of organisms for which robust
genetic tools are not available.
Despite the numerous design requirements and con-
straints, many biochemical transformation projects in
biotechnology have been realized. Here, we highlight four
types: (i) incorporating nonnative genes to extend nat-
ural metabolism, (ii) incorporating whole pathways to
add function, (iii) creating new pathways that have never
existed before in nature, and (iv) organizing pathways to
enhance activity (e.g., through compartmentalization or
scaﬀolds). It should be noted that signiﬁcant engineering
of host metabolism is often a necessity to ensure precursor
availability and inhibition of competitive pathways [12].
Moreover, in many cases the scope of genetic modiﬁcations
requires multiple approaches to achieve a desired user-
deﬁned objective [13–15].
To extend natural metabolism, network optimization
and selection of nonnative enzymes that catalyze the forma-
tion of a desired biochemical is required. In one example
of this approach, Liao and colleagues converted 2-keto acid
metabolites into branched alcohols for use as biofuels [13].
This was accomplished in Escherichia coli by ﬁrst engineering
the amino acid biosynthetic pathways that supply precur-
sors required for 2-keto acid metabolite production. Then,
incorporation of 2-keto acid decarboxylases and alcohol
dehydrogenases from a variety of organisms yielded the
desired alcohols. In later work, Atsumi et al. improved
production titers for isobutanol through the use of alcohol
dehydrogenases from diﬀerent organisms, Saccharomyces
cerevisiae and Lactococcus lactis, rather than the native
alcohol dehydrogenase of E. coli [16]. In another example,
an E. coli strain was engineered to convert simple sugar to
biodiesel through modiﬁed fatty-acid biosynthesis pathways
[15]. Here, native host metabolism was reprogrammed by
modulating more than 8 enzymes (such as thioesterase, acyl-
ligase, and wax ester synthase) to overproduce fatty acids,
deregulate fatty acids, and produce fatty acid ethyl and
methyl esters (biodiesel). Then, incorporation of nonnative
hemicellulase genes enabled direct conversion of biomass
to biodiesel in a single E. coli strain. Other poignant
examples of heterologous gene transfer have come from
meeting global health needs, namely, the treatment of
malaria. In a landmark study, production of the antimalarial
drug artemisinin required incorporation of amorphadiene
synthase and cytochrome P450 monoxygenase from the
plant Artemisia annua [14]. These genes were incorpo-
rated into a strain of S. cerevisiae modiﬁed to produce
large quantities of the amorphadiene precursor, farnesyl
pyrophosphate, by a complete overhaul of the mevalonate
pathway.4 Journal of Biomedicine and Biotechnology
Beyond heterologous gene transfer, protein engineering
is being explored to create nonnatural enzymes that can
be combined with biosynthetic pathways to create novel
biochemical products. New enzymes can be created through
either mutagenesis of existing enzymes or rational design of
new enzymes. For example, Liao and colleagues expanded
their work on the biosynthesis of alcohols by utilizing
promiscuous enzyme activity [17]. By altering substrate
speciﬁcity of an enzyme through site-directed mutagenesis,
they were able to synthesis enzymes to make nonnatural
alcohols with possible value as biofuels. A similar approach
was used to develop substrate-speciﬁc cytochrome P450
enzymes [18]. These enzymes were created through random
and site-directed mutagenesis to selectively deprotect diﬀer-
ent monosaccharide substrates for polysaccharide synthesis.
In addition, protein engineering has advanced to a point
where design of new enzymes from scratch is possible.
An enzyme to perform a Diels-Alder reaction was created
through computational design and experimental ﬁne-tuning
to achieve substrate speciﬁcity and stereoselectivity [19]. The
designed enzyme was then altered to demonstrate the ability
to perform similar reactions with diﬀerent substrates. Such
work demonstrates a powerful new approach to achieving
molecular transformations that cannot be eﬃciently per-
formed by either nature or conventional chemistry.
As the number of nonnative and unnatural genes
transferred into a host increases to include entire pathway
branches,acriticalconsiderationisseamlessintegrationwith
the organism’s regular metabolic functions. One issue with
metabolicnetworktransferisthattheglobalenergyresources
of the cell must support both synthetic modules and the
host cell. Despite this challenge, as well as other hurdles
associated with constructing, testing, and balancing large
networks of molecular pathways (where design complexity
can be intimidating), some examples have shown success.
Twonotableapplicationsincludeproductionofhighbutanol
titers through the transfer of the Clostridium acetobutylicum
butanol pathway to a variety of bacterial hosts [20]a n dp r o -
duction of valencene in yeast by transferring an isoprenoid
pathway consisting of 7 E. coli genes [21].
In addition to manipulating and extending native path-
ways, it is also possible to engineer novel biochemical
pathways that have never been observed in biology. For
example, Moon et al. designed a synthetic pathway using
genesfromthreesources:myo-inositol-1-phosphatesynthase
from S. cerevisiae, myo-inositol oxygenase from mice, and
uronatedehydrogenasefromPseudomonassyringae[22].The
novel combined pathway was inserted into E. coli to convert
myo-inositol into glucaric acid, a value-added chemical used
as a dietary supplement, therapeutic, and potential feedstock
for polymers. Similarly, Hawkins and Smolke synthesized
benzylisoquinoline alkaloids in S. cerevisiae through the
combination of genes from three diﬀerent plant species as
wellhumanP450enzyme[23].Theseexamplesillustratethat
complex molecules of therapeutic interest may be produced
by combining existing enzymes into novel assemblies to
create novel biosynthetic pathways.
Protein scaﬀolds that hold tagged pathway enzymes in
close proximity have also been used to improve biochemical
transformations [24]. In this model, scaﬀolds have been
designed for biosynthesis pathways including mevalonate
and glucaric acid pathways, and spatial colocalization of
pathway enzymes has lead to increased productivity [24].
The use of scaﬀolds increases the local concentration
of pathway intermediates near the desired downstream
enzymes, which improves overall pathway kinetics, avoids
theaccumulationofhazardousintermediates,andminimizes
consumption of intermediates by competing pathways [25,
26]. Such synthetic biology tools provide novel mechanisms
for manipulating metabolic pathways and complement tra-
ditional pathway optimization.
Characterizingtranscriptionalandtranslationalarchitec-
tures and developing technologies for manipulating these
processes provide other useful approaches for engineering
microbial biotransformations. For instance, new genetic
elements have been created to carry out circuit-like regula-
tion that mimic toggle switches, AND gates, and oscillators
[27–29]. Inserting such regulatory elements into cellular
devices could lead to high-resolution control and novel
functional behavior. Posttranscriptional regulation is also
possible. Translation eﬃciency, for example, can be adjusted
by modifying ribosome binding site aﬃnity [30].
To ﬁne-tune imperfect designs, genetic screening and
evolutionary tools are also being developed. Sommer et al.
screened a metagenomic library of arbitrary environmental
DNA to identify three novel genes that convey tolerance
to the biomass chemicals syringaldehyde and 2-furoic acid
[31]. Similarly, Bayer et al. used a metagenomic screen of
89 suspected methyl halide transferase enzymes in E. coli
to increase the yield of methyl halides from biomass to
s e r v ea sp r e c u r s o r sf o rc h e m i c a l sa n df u e l s[ 32]. Another
screening technique called SCALEs (scalar analysis of library
enrichments) uses libraries consisting of genomic DNA
inserts of speciﬁc sizes to identify regions of a genome
responsibleforaparticularphenotype [33].Thismethodhas
been used to identify gene regions conveying tolerance to
inhibitorsofmetabolicpathwaysinvolvingasparticacid[34].
Such screens demonstrate approaches that can be used to
discover genes responsible for other desirable or undesirable
phenotypes. New robust evolutionary techniques such as
multiplex automated genome engineering (MAGE) and
global transcription machinery engineering (gTME) have
also been developed to enable rapid ﬁne-tuning of metabolic
networks. MAGE generates genomic diversity within cells
andacrosspopulationsbyusingparallel,site-speciﬁcmodiﬁ-
cationofDNA.UsingMAGE,thelycopenesynthesispathway
in E. coli was optimized by genetically modifying several
targeted chromosome locations associated with genes of the
pathway[35].ThegTMEapproachusesrandommutagenesis
of transcriptional machinery to alter the transcriptional
p r o g r a mo fa no r g a n i s ma n dh a sb e e nu s e dt od e v e l o pE.
coli and S. cerevisiae strains with desirable phenotypes for
biofuel production, such as high ethanol tolerance [36, 37].
Evolutionary approaches provide a complementary strategy
to design-based engineering that may reveal unexpected
routes toward higher system performance and provide a
better understanding of biological systems that may be
incorporated into subsequent design strategies.Journal of Biomedicine and Biotechnology 5
The next few years will bring increased attempts to con-
struct and program large-scale user-deﬁned pathways, and
even whole organisms. Recently, researchers at the J. Craig
Venter Institute (JCVI) assembled, modiﬁed, and implanted
ac o m p l e t eMycoplasma mycoides donor genome into a
related Mycoplasma recipient cell [38]. This technological
milestone marks the dawn of synthetic genomics. While
this achievement is an important step towards designer
organisms,applications of this approachremainchallenging.
For example, if one knew how to design a cell that eﬃciently
converts sunlight, water, and CO2 into fuel, then JCVI’s
technology could enable the synthesis and transplantation
of that chemically synthesized genome into a recipient
cell. However, we do not yet know how to design such a
genome from scratch, and simply screening astronomical
numbers of synthetic genome variants is impractical or even
impossible. In addition, the costs of genome construction
currently prohibit most researchers from applying this
approach. In the long run, however, there is no doubt that
JCVI’s technology will join a suite of other whole-genome
engineering techniques to accelerate the development of
microbial factories for producing fuels, pharmaceuticals,
green biochemicals, and novel materials.
2.2. Cellular Devices and Therapies. For applications in
medicine, synthetic biology may also be used to create new
cellular functions, such that the engineered cell itself—not
just a product that it produces—serves a therapeutic role. In
this context, a cell can be viewed as a device that receives
inputs, processes this information, and produces outputs
all based upon its genetic programming. Therefore, novel
cellular functions may be constructed through strategies
that create new connections between existing and novel
mechanisms for input (e.g., receptors), processing (e.g.,
intracellular signaling cascades and regulatory interactions),
and output (e.g., the production of bioactive molecules or
theinductionofspecializedcellulareﬀectorfunctions).Every
such strategy must take into account both bottom-up con-
siderations (including the choice of biological parts and their
conﬁguration) and top-down considerations (including the
choice of cell type to be engineered and the interactions—
both desirable and undesirable—of the engineered compo-
nents with native cellular functions) (Figure 2). Each of these
design choices is guided by the type of cellular function
required for a given application.
For some strategies, a cell may be reprogrammed to
change the way it relates existing inputs to existing outputs
by rewiring intracellular signal processing. In one example
of this approach, signaling through the ErbB2 receptor
tyrosine kinase, which mediates mitogenic or transformative
signaling in tumor cells, was redirected into a proapoptotic
pathway [39]. This was accomplished by engineering novel
intracellular signaling proteins, in which SH2 or PTB
phosphotyrosine-recognition domains from Grb2 or ShcA,
respectively, (which interact with ErbB2), were fused to the
death eﬀector domain of Fadd. Such intracellular signaling
proteins can be engineered to modulate multiple functional
characteristics, including autoregulation, ligand speciﬁcity,
and signaling dynamics using modular functional domains
[40, 41]a n dv a r i o u ss c a ﬀold motifs and conﬁgurations [42].
An alternative approach is one often used in basic research,
whereby the extracellular ligand-binding domain of one
receptor is fused to the intracellular signaling domain of
another receptor to generate a chimeric receptor. Strategies
such as these could be used to generate cellular therapies
for situations in which the natural input/output relationship
is dysfunctional, such as tumor-mediated conversion of
tumor-reactive T cells to an immunosuppressive phenotype.
An important consideration when using this approach is
that the engineered signaling pathway does not replace
native signaling pathways, but rather engineered and native
pathways are coupled by the shared use of native receptors or
downstream components.
In other applications, cells may be engineered to respond
to a stimulus to which the cell does not naturally respond.
An early example of this approach is the use of chimeric
antigen receptors (CARs) for cancer immunotherapy. In
this model, ligand-binding domains from antibodies speciﬁc
for tumor antigens are fused to the intracellular portion
of T cell receptors in order to generate T cells capable of
killing tumor cells that express the targeted antigen. Early
implementations of this approach are in clinical trials, and
while most beneﬁts have been modest, some responses are
quite promising [43]. In the most recent version of this
strategy, third generation CARs are constructed by fusing
the ligand-binding domains of tumor-speciﬁc antibodies
to intracellular domains of CD28, CD137, and the TCR-
ζ chain, in sequence [44]. In this construct, the TCR-ζ
chain confers TCR signaling upon binding of the antibody
domain to its target, while the CD28 and CD137 domains
enhanceTCRsignalingandTcellsurvivalinvivo.Inarelated
approach, Xu et al. constructed tumor-responsive dendritic
cells that recognize the tumor antigen, erbB2, and signal
through the Toll-like Receptor 4 (TLR4) pathway to induce
an inﬂammatory immune response against the tumor [45].
This was accomplished by fusing the ligand-binding domain
of an anti-erbB2 antibody to various intracellular mediators
of TLR4 signaling [45]. While each of these examples used
receptors or antibodies that naturally recognize a particular
ligand, it is also possible to re-engineer receptors, such as
GPCRs, so that they respond to novel small molecule ligands
[46]. Such an approach may be applied to generate cells
whose functions are regulated by an inducible trigger, such
as a small molecule drug. As an example of this strategy,
T cells were engineered to express interleukin 2 (IL-2, a
cytokine necessary for T cell survival) under the control of
a synthetic ribozyme switch that responds to the inducer
theophylline. When these cells were transferred to recipient
mice, theophylline treatment induced IL-2 production and
engineered T cell survival in vivo [47]. Similar ribozyme
switches may be designed to respond to a variety of small
molecule cues. Other RNA-based approaches can be used
to program cells to perform more complicated functions,
including the logical evaluation of multiple inputs, such
that activation of a target gene (or genes) is conditioned
upon the presence or absence of multiple extracellular cues
[48].6 Journal of Biomedicine and Biotechnology
Like mammalian cells, bacteria may also be programmed
for therapeutic applications in which the bacteria itself is
the therapeutic. For example, bacteria naturally home to
tumor environments, so this propensity may be harnessed by
engineering bacteria to selectively invade and destroy cancer
cells in vivo [49]. In this model, bacteria were engineered
to express the invasin protein in response to the hypoxic
conditions that typify tumor microenivronments. Invasin
expression enables these bacteria to invade mammalian cells
expressing β1-integrins, which is a common marker on some
types of cancer. This approach can be further enhanced
to include the hypoxia-inducible release of cytotoxic agents
to destroy the tumor cells after invasion [49]. Similarly,
synthetic biology could be used to integrate more complex
functions and regulatory features into other bacteria-based
therapeutics. Important considerations when manipulating
bacteria for therapeutic applications include both inter-
actions with host biology and preventing the engineered
bacteriafromspreadingbeyondthepatientbeingtreated.For
example, Lactococcus lactis was engineered to treat inﬂam-
matory bowel diseases by programming these microbes
to secrete the immunosuppressive cytokine Interleukin-10
(IL-10) and by deleting their thymidylate synthase gene
[50]. This strategy restricted bacterial growth to cultures
supplemented with thymidine, which prevents these cells
from replicating eﬃciently in the gut. This treatment has
already shown promise in clinical trials [51]. Because the
engineered bacteria die quickly within the gut, however,
frequent treatments would be required to treat chronic
disease. Synthetic biology could be used to overcome such
limitations. For example, the immunosuppressive bacteria
described above could be modiﬁed such that they require
survival signals from the gut and quickly die outside of this
environment, or such that they secrete IL-10 only when they
detect disease ﬂareups. Such modiﬁcations could allow for
safer and more eﬀective treatments while still restricting
these bacteria to their targeted milieu. Synthetic biology
provides the framework required to design and implement
such sophisticated biotherapy strategies.
Engineering communication between cells also may be
useful for therapeutic applications. Already, simple synthetic
communication systems have been constructed in bacteria,
yeast, and even mammalian cells. In a representative exam-
ple, a yeast “sender” population was engineered to secrete
the plant hormone, isopentenyladenine, and a “receiver”
yeast population was made responsive to this signal by
expressing the receptor protein, AtCRE1 [52]. Bidirectional
communication can also be used to coordinate multicel-
lular functions. For example, two populations of E. coli
were engineered to communicate bidirectionally using P.
aeruginosa quorum sensing components, such that each
cell type secretes a unique “sender” signal and expresses
its own reporter gene only when it detects the signal
secreted by the other cell type [53]. Similar information
exchange between sender and receiver cells can also be
used to program spatial organization and pattern formation
[54]. Other applications of intercellular communication
are “polling” strategies, which can be used to coordinate
and synchronize dynamic cellular functions and potentially
improve performance by reducing sensitivity to variations
in environmental conditions [55]. These approaches can
also be extended to interkingdom communication, including
bacterial, yeast, and mammalian cells [56]. When applied in
mammalian cells, such approaches could eventually be used
to program communication and spatial organization for the
construction of synthetic organs or organ-like devices. These
strategies may also provide useful tools for programming the
diﬀerentiationofstemcellsinamannerthatdoesnotrequire
recapitulatingthecomplexextracellularcuesthatguidenatu-
ral diﬀerentiation programs. Interkingdom communication
platforms could enable engineered symbiotic microbes,
which might patrol the colon or skin for signs of disease,
to communicate this information to their human hosts.
To date, existing intercellular communication systems rely
upon simple small molecule-based signaling intermediates,
and sophisticated multicellular communication strategies
will require the development of novel orthogonal, high-
information-content signaling platforms.
Finally, synthetic biology could lead to new therapeutics
through in vitro applications such as screening and diagnos-
tics. Current drug screens are typically based upon measure-
ments such as treatment-induced changes in the replication
and viability of diseased cells relative to changes in healthy
control cells. This limits the type of information about bio-
logicalactivityandsafetythatcanbeassessedatthescreening
stage. Screens constructed through synthetic biology can be
used to evaluate more complicated biological eﬀects. For
example, engineered cells can be used to identify drugs that
target speciﬁc pathogen functions. Such an approach was
used to identify substances that block the M. tuberculosis
protein, EthR, which otherwise confers resistance to the
prodrug ethionamide [57]. This approach may be especially
useful for pathogens that are dangerous or diﬃcult to culture
in vitro. Similar approaches could be used to construct
screens that evaluate the impact of test molecules on human
cellular functions that do not naturally produce an easily-
assessed phenotype like apoptosis. Synthetic biology may
also be useful for the construction of biological diagnostics.
For example, bacterial bioreporters have been constructed to
detect various compounds and toxins [58]. In most cases,
this detection relies upon natural sensing mechanisms and
involves expressing a reporter gene in response to the acti-
vation of an existing bacterial promoter. Synthetic biology
could be employed to engineer novel sensing mechanisms
and build bacterial bioreporters that perform diagnostic
assessments such as detecting biochemical markers within
human blood samples. These technologies could be designed
to function and produce readouts without requiring external
equipment, so that they could be readily deployed for mobile
operations or in resource-poor areas. As we continue to
develop improved technologies for engineering both human
cells and the microorganisms with which they interact,
synthetic biology promises to transform medicine just as it
has already begun to transform biotechnology.
2.3. Expanding the Chemistry of Life: Novel Biopolymer Syn-
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that often hamper design goals, modules of nonnatural
components that operate independently of the cell’s natural
machinery are envisioned. Such orthogonal modules oﬀer
tremendous ﬂexibility for optimization without disrupting
the cell’s operating system and, as a bonus, could exploit the
renewability and evolvability of biology to synthesize nonbi-
ological materials. In nature, complex and diverse chemical
tasks are carried out across a variety of length scales using
biopolymers of very simple composition. The expansion of
the central dogma of biology to include diverse, nonnatural
analogs may lead to a set of general solutions featuring
orthogonal information coding, orthogonal cellular machin-
ery,orthogonalscaﬀolds,orthogonalcompartments,orthog-
onal interactions, or orthogonal communication pathways,
which could form the basis for entirely artiﬁcial living
systems. As an example, even minor modiﬁcations to natural
biopolymers can endow them with altered interactions
and enhanced functionalities. Peptide nucleic acids (PNAs),
which have backbones similar to peptides but nucleobase
functional groups (as opposed to the twenty natural amino
acids) [59], hybridize to short stretches of DNA, and exhibit
increased resistance to both proteases and endonucleases.
To expand the chemistry of life, orthogonal modules
may be constructed through evolved catalytic ensembles that
enable synthesis, evolution, and organization of nonnatural
or hybrid polymers. In this case, bottom-up design consider-
ations must include template recognition, substrate recogni-
tion, catalytic activity, error correction, product folding, and
t r a n s p o r tp r o p e r t i e s( Figure 2). Top-down considerations
may require that synthesis should occur under physiological
conditions (temperature, buﬀer conditions, etc.) and that
monomer building blocks must be available to the host or
able to be synthesized by the host. Implicit mass transfer
limitations arising from cellular structure must also be
addressed.
Increasing the capacity of nucleic acids to store, recall,
and propagate speciﬁc information can augment genomic
information [60, 61]. Early experiments with modiﬁed
nucleic acids (termed xenonucleic acids, or XNAs [62]) were
motivated by the desires to understand how DNA and RNA
developed in the prebiotic world [63] and to create antisense
molecules that could be easily taken up by cells [64]. More
recently, eﬀorts have shifted towards modulating function
by exploring diversity in the composition of bases [65],
sugars [61], and phosphates [61]. Backbone modiﬁcations
of natural nucleic acids generally decrease recognition by
endonucleases and provide an alternative strategy for mod-
ulating XNA binding aﬃnity to complementary strands.
The most studied backbone modiﬁcations of natural nucleic
acids include PNAs [59], locked nucleic acids (LNAs) [66],
threose nucleic acids (TNAs) [67], phosphorothioates [68],
and Morpholinos [69]. Beyond antisense applications, these
XNAs have the potential to vastly expand biopolymer
information storage.
In order for novel biopolymers to become a viable
tool for synthetic biologists, sequence-deﬁned synthesis of
the polymers is required. Beyond low-eﬃciency solid phase
synthesis techniques, enzymatic template-directed synthesis
of nonnatural polymers can be performed. In one approach,
naturally occurring DNA and RNA polymerases have been
identiﬁed that accept nonnatural substrates, thus allowing
the templated synthesis of TNA from DNA [70]. In addition,
these polymerases can be evolved in vitro to improve pro-
cessivity and decrease error rates with nonnatural monomer
units [71]. Improved understanding of structure-function
relationships in polymerases has further resulted in the
rational modiﬁcation of a natural transcriptase to a poly-
merase that accepts nonstandard nucleotides [72]. This
illustrates how directed evolution can be incorporated into
the design cycle. Advances in enzyme engineering and our
understanding of nature’s design rules will speed progress
toward engineered polymerases and enable us to probe the
feasibility of enzymatic XNA synthesis and application.
In another approach, the cell’s protein polymerase,
the ribosome, could be engineered to selectively accept
and polymerize synthetic monomers with high template
ﬁdelity. Driven by the promise of new therapeutics, evolvable
abiological polymers, and biophysical probes, there has long
been interest in harnessing natural translation machinery to
synthesize polymers of nonnatural building blocks [73]. In
concept, ribosome engineering may provide a more general,
modular solution to novel biopolymer synthesis due to the
use of transfer RNAs (tRNAs) that serve as adapters between
the genetic code and the biopolymer product. Incorporat-
ing nonnatural monomer units on the ribosome depends
on (i) reassignment of codons to nonnatural monomer
units and (ii) acceptance of these units in the catalytic
center. Remarkably, dozens of nonnatural amino acids have
already been site-speciﬁcally incorporated into polypeptides
by the ribosome. This was accomplished by engineering
synthetic routes toward aminoacylation of tRNAs [74, 75]
and orthogonal synthetase-tRNA pairs [76] and showing
that natural ribosomes could accept nonnatural substrates.
Even nonpeptide backbones, such as N-substituted amino
acids [77] and hydroxy acids [78] have been incorporated
by the ribosome, although with varying degrees of suc-
cess. When using orthogonal synthetase-tRNA pairs, one
potential issue is nonspeciﬁc incorporation that results
from competing natural aminoacyl-tRNAs. To obtain greater
controlofhomogeneoussequencecomposition,geneticcode
reprogramming [79, 80] or synthetic genetic systems (based
on XNAs or modiﬁed bases) can be applied.
Although a variety of nonnatural monomer units have
been incorporated by native ribosomes, it is clear that
these substrates are inherently suboptimal. The tuning of
polymerase machines to their natural substrates is exquisite
[81]. Therefore, a major design challenge lies not only in
the bottom-up aspect of incorporating nonnatural building
blocks, but also in reversing the evolutionary optimization
of ﬁnely tuned machinery and aligning it onto an entirely
new path. To address this limitation, the ribosome and its
machinery can be modiﬁed to enable increased promiscuity
and eﬃciency at polymerizing nonnatural monomer units.
In one case, EF-Tu was evolved to more eﬃciently incor-
porate amino acids containing bulky aromatic groups [82].
In examples that modify the ribosome directly, ribosomal
RNA has been mutated or chemically modiﬁed to enable
more eﬃcient nonnatural substrate incorporation [83, 84].8 Journal of Biomedicine and Biotechnology
Although the ribosome has been shown to be tolerant of
modiﬁcations, there are relatively few examples because
constraints imposed by living cells (e.g., dominant lethality)
have hindered eﬀorts to engineer ribosomes.
Specialized ribosomes overcome the dominant lethality
constraint and provide an exemplary illustration of orthog-
onal performance. Originally pioneered by de Boer and
colleagues [85], anti-Shine-Dalgarno sequences can be engi-
neered into 16S ribosomal RNA to enable a group of ribo-
somes(orthogonalfromthehost)totranslatespeciﬁcmRNA
populations.Thishasshownadvantagesforperforminglogic
operations [85, 86], synthesizing proteins with nonnatural
amino acids, such as p-benzoyl-(L)-phenylalanine [87], and
eﬃciently incorporating quadruplet codons [88]. Orthog-
onal ribosomes will provide useful tools in programming
synthetic function and expanding the genetic code to make
nonnatural products for biotechnology.
Cell-freesystemsarebeingusedtoremovethemoststrin-
gent top-down design constraints confronted when attempt-
ingtoexpandthechemistryoflife[89–92].Cellularoverhead
is reduced (e.g., genes of unknown functions, metabolic
redundancies, and unintended interactions), transport bar-
riers are removed, cellular viability is not required, and
resources are more eﬃciently directed towards user-deﬁned
objectives. An additional advantage is direct access to the
system of interest, similar to opening the hood of a car and
accessing the engine. Cell-free protein synthesis systems [93–
95] are one of the most prominent examples of cell-free
biology and can be employed to create large amounts of
nonnatural peptide [96]. Complex systems of biochemical
transformations can also be built [97]. Looking forward,
both in vitro and in vivo eﬀorts towards novel catalytic
ensembles promise to meld the complexity and diversity of
chemistry with the accuracy and reproducibility of biology.
Themainrewardswillbeincreasedunderstandingofbiology
and new classes of evolvable molecules, which may ﬁnd use
as therapeutics or novel materials.
3.MovingForward
Given the complexity that characterizes living systems devel-
oped through eons of evolution, the challenge to transform
biology into an engineerable system is formidable. Consid-
ering biological design from both top-down and bottom-
up perspectives provides a useful framework for proceeding
towards this goal. At each scale of biological organization,
this approach guides both the design and analysis of novel
systems, as well as our investigations into the fundamental
mechanisms that impact the performance of engineered
biological systems. Synthetic biology is already changing the
way we think about producing useful molecules, engineering
our own biology, and expanding the chemistry of life.
Making progress on these and other fronts will require
both interdisciplinary approaches and new pedagogical
strategies for training a new cadre of whole-brain thinkers. If
successful, these eﬀorts may revolutionize our ability to meet
pressing societal needs through a new paradigm of biology
by design.
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